Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lung Neoplasms × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Prostatic Neoplasms 4 Ovarian Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Primary Myelofibrosis 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Polycythemia Vera 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Myeloproliferative Disorders 1 Multiple Myeloma 1

Interventions

pembrolizumab 48 Carboplatin 41 Pemetrexed 35 Specimen Handling 34 Magnetic Resonance Spectroscopy 34 Cisplatin 26 Blood Specimen Collection 24 Paclitaxel 16 durvalumab 14 Radiosurgery 14 Radiotherapy 13 osimertinib 12 Nivolumab 12 Gemcitabine 12 Biopsy 12 Bevacizumab 12 atezolizumab 11 Practice Guidelines as Topic 10 Educational Status 9 Docetaxel 9 130-nm albumin-bound paclitaxel 9 X-Rays 8 Standard of Care 8 Immunoglobulin G 8 Taxes 7 Surveys and Questionnaires 7 Etoposide 7 Drug Therapy 7 Disulfides 7 Cetuximab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04170946 2026-03-05

Talazoparib

University Health Network, Toronto

Phase 1 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡